目的 研究利拉魯肽對(duì)高血脂小鼠體質(zhì)量和血清中總膽固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL-C)及高密度脂蛋白(HDL-C)的影響。方法 將40只小鼠,隨機(jī)分為對(duì)照組、模型組、陽(yáng)性組及利拉魯肽低、高劑量組。對(duì)照組飼喂基礎(chǔ)飼料,其余4組均飼喂高脂飼料。對(duì)照組和模型組均ip生理鹽水,陽(yáng)性組ig辛伐他汀,利拉魯肽低、高劑量組每日分別ip 200、400μg/kg利拉魯肽1次,連續(xù)4周。實(shí)驗(yàn)結(jié)束處死小鼠,稱質(zhì)量,檢測(cè)各組小鼠給藥前后血清中TC、TG、LDL-C、HDL-C水平,并計(jì)算動(dòng)脈粥樣硬化指數(shù)(AI)和抗動(dòng)脈粥樣硬化指數(shù)(AAI)。結(jié)果 與對(duì)照組相比,模型組小鼠體質(zhì)量及血脂指標(biāo)明顯升高;與模型組相比,陽(yáng)性組、利拉魯肽低、高劑量組小鼠體質(zhì)量及血脂指標(biāo)明顯降低,且利拉魯肽的效果明顯優(yōu)于辛伐他汀;與模型組相比,利拉魯肽低劑量組的AI顯著性降低,利拉魯肽高劑量組的AAI顯著升高。結(jié)論 利拉魯肽能具有很好的調(diào)血脂、抑制動(dòng)脈粥樣硬化的功效,在預(yù)防心血管疾病方面具有很好的應(yīng)用前景。

Objective To study the effect of liraglutide on body weight and total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), and high density lipoprotein (HDL-C) in serum of hyperlipemia mice. Methods Forty mice were randomly divided into basic group (NFD), high-fat group (HFD), simvastatin group (SIM+HFD), low-dose liraglutide group (LL+HFD), and high-dose liraglutide group (HL+HFD). The mice in NFD group were fed with the basal diet, while the mice in other four groups were fed with the high-fat diet. Besides, the mice in both NFD and HFD groups were ip administered with saline, the mice in SIM+HFD group were ig treated with simvastatin daily, the mice in LL+HFD and HL+HFD groups were ip injected with liraglutide (200 and 400 μg/kg), respectively. Four weeks later, mice were sacrificed and weighed, and the levels of TC, TG, LDL-C and HDL-C in serum were measured, and then atherosclerosis index (AI) and anti-atherosclerosis index (AAI) were further calculated. Results Compared with mice in NFD group, the body weight and levels of serum TC, TG, and LDL-C in mice of HFD group were significantly increased. Compared with mice in HFD group, mice in SIM+HFD, LL+HFD, and HL+HFD groups exhibited much lower body weight and levels of serum TC, TG, LDL-C, and HDL-C. Furthermore, the results also showed that the effect of liraglutide was higher than those of simvastatin, the positive control drug. In addition, compared with mice in HFD group, AI of mice in the LL+HFD group was decreased, and AAI of mice in the LL+HFD group was significantly increased. Conclusion Liraglutide can significantly improve the weight of obese mice fat diet induced obese mice weight gain, dyslipidemia, and the effect is better than that of the positive control drug simvastatin. In addition, liraglutide also have a good effect on prevention of ahterosclerosis.